Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ibrutinib vs Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed (CLL)

NCT02007044 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02007044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02007044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ibrutinib vs Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed (CLL)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 6, 2013
Completion date
June 30, 2028
Enrollment
66 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prolymphocytic leukemia, recurrent chronic lymphocytic leukemia, recurrent small lymphocytic lymphoma